Evaluation of salmeterol xinafoate plus fluticasone propionate for the treatment of chronic obstructive pulmonary disease

Ruben D. Restrepo, Andrew Tate, Joshua Coquat

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Introduction: Current clinical guidelines recommend long-acting bronchodilators as the mainstay of the pharmacotherapy of patients with chronic obstructive pulmonary disease (COPD). Inhaled corticosteroids (ICS), in conjunction with long-acting beta-agonists (LABA), are routinely considered at severe and very severe stages of COPD when patients lack adequate response to single-therapy with LABAs. Although the study methodologies evaluating the clinical effectiveness of the combination therapy using salmeterol and fluticasone (SAL/FLU) for patients with COPD have been questioned, a number of studies have suggested that using ICS, in combination with a LABA agent, may improve survival of patients with COPD. Areas covered: This article attempts to review the most current evidence for using SAL/FLU in the management of COPD and summarizes the results of outcome measures reported in randomized controlled trials. Expert opinion: Until new forms of drug combinations are made available, the use of dual-therapy containing a LABA and ICS remain as the most logical and appropriate approach for the treatment of patients suffering from severe and very severe COPD with repeated exacerbations.

Original languageEnglish (US)
Pages (from-to)1993-2002
Number of pages10
JournalExpert Opinion on Pharmacotherapy
Volume14
Issue number14
DOIs
StatePublished - Oct 1 2013

Keywords

  • Chronic obstructive pulmonary disease
  • Combination therapy
  • Exacerbations
  • Fluticasone propionate; inhaled corticosteroids long-acting bronchodilators
  • Salmeterol xinafoate

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Evaluation of salmeterol xinafoate plus fluticasone propionate for the treatment of chronic obstructive pulmonary disease'. Together they form a unique fingerprint.

  • Cite this